Abstract
A 23-year-old man presented to a referring hospital emergency room with gradually worsening throat pain. He was febrile to 38.4°C and his exam was notable for very large, erythematous tonsils. His labs were notable for a white blood cell (WBC) count of 119.8 K/cu mm (3.50–10.80 K/cu mm) with 91% blasts, creatinine elevated to 1.63 mg/dL (0.70–1.30 mg/dL), and lactate dehydrogenase (LDH) of 1122 U/L (≤250 U/L). Computed tomography (CT) of the neck was remarkable for the enlargement of tonsils and lymph nodes with a narrowing of the nasopharyngeal airway. He was started empirically on cefepime and transferred to a tertiary care intensive care unit (ICU) due to concern for impending airway compromise in the setting of likely new acute leukemia. Upon arrival, his peripheral blood smear was notable for numerous circulating blasts with a high nuclear to cytoplasmic ratio, a moderate amount of basophilic cytoplasm, open chromatin, and prominent nucleoli suggestive of monoblastic differentiation. Flow cytometry confirmed an immunophenotype consistent with acute myeloid leukemia (AML).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209–21.
Schuurhuis GJ, Heuser M, Freeman S, et al. Minimal/measureable residual disease in AML: consensus document from ELN MRD Working Party. Blood. 2018;131:1275–91. Epub ahead of print.
Doehner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136–52.
Nass SJ, Beaupin LK, Demark-Wahnefried W, et al. Identifying and addressing the needs of adolescents and young adults with cancer: summary of an Institute of Medicine workshop. Oncologist. 2015;20(2):186–95.
Rechis R, Bann C, Arvery S, et al. Unique risks & vulnerabilities of AYA patients across the lifespan, LIVESTRONG Foundation: AYA survey results. Presented at Institute of Medicine National Cancer Policy Forum/LIVESTRONG Workshop on Addressing the Needs of Adolescents and Young Adults with Cancer, Washington, DC; 2013.
Sekeres MA, Elson P, Kalaycio ME, et al. Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients. Blood. 2009;113(1):28–36.
Massarotti C, Scaruffi P, Lambertini M, et al. State of the art on oocyte cryopreservation in female cancer patients: a critical review of the literature. Cancer Treat Rev. 2017;57:50–7.
Johnson MD, Cooper AR, Jungheim ES, et al. Sperm banking for fertility preservation: a 20-year experience. Eur J Obstet Gynecol Reprod Biol. 2013;170:177–82.
Chung K, Irani J, Knee G, et al. Sperm cryopreservation for male patients with cancer: an epidemiological analysis at the University of Pennsylvania. Eur J Obstet Gynecol Reprod Biol. 2004;113S:S7–S11.
Auger J, Sermondade N, Eustache F. Semen quality of 4480 young cancer and systemic disease patients: baseline data and clinical considerations. Basic Clinical Androl. 2016;26(3):1–10.
Burns KC, Hoefgen H, Strine A, Dasgupta R. Fertility preservation options in pediatric and adolescent patients with cancer. Cancer. 2018;124(9):1867–76. https://doi.org/10.1002/cncr.31255. Epub 2018 Jan 25.
Banerjee R, Tsiapali E. Occurrence and recall rates of fertility discussions with young breast cancer patients. Support Care Cancer. 2016;24:163–71.
Deruyver Y, Vanderschueren D, Van der Aa F. Outcome of microdissection TESE compared with conventional TESE in non-obstructive azoospermia: a systematic review. Andrology. 2014;2:20–4.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Review Questions and Answers
Review Questions and Answers
-
Q1.
What is NOT a barrier to preserving fertility for those with cancer requiring chemotherapy?
-
(a)
Providers taking the time during a busy period to go over the risks to fertility
-
(b)
Cost of fertility-preserving measures
-
(c)
Medical status of the patient
-
(d)
Importance of fertility preservation to patients
-
(e)
Available facilities for fertility preservation
-
(a)
-
A1.
(d)
-
Q2.
True or false? There have been reports of transferring leukemia through egg or sperm preservation.
-
A2.
False
-
Q3.
What percentage of patients remembers discussing the impact of fertility of therapy with his/her provider?
-
(a)
10%
-
(b)
25%
-
(c)
50%
-
(d)
65%
-
(e)
90%
-
(a)
-
A3.
(c)
-
Q4.
What is the best option for a male patient who has reached sexual maturity but is unable to provide semen and still wishes to preserve fertility?
-
(a)
Nothing
-
(b)
TESE
-
(c)
Sexual education
-
(d)
Only offering fertility treatment following therapy
-
(a)
-
A4.
(b)
-
Q5.
True or false? Men with leukemia have decreased sperm counts in comparison to their healthy peers and to those of similar age with chronic diseases making sperm backing successfully more challenging.
-
A5.
True
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
DuVall, A.S., Hedges, J.C., Hayes-Lattin, B. (2019). Case Presentation: Sperm Banking in Patient Diagnosed with Acute Myeloid Leukemia. In: Woodruff, T., Shah, D., Vitek, W. (eds) Textbook of Oncofertility Research and Practice. Springer, Cham. https://doi.org/10.1007/978-3-030-02868-8_51
Download citation
DOI: https://doi.org/10.1007/978-3-030-02868-8_51
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-02867-1
Online ISBN: 978-3-030-02868-8
eBook Packages: MedicineMedicine (R0)